ProPhase Labs Stock Forecast, Price & News

+0.13 (+2.29 %)
(As of 06/17/2021 12:10 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume2,122 shs
Average Volume346,559 shs
Market Capitalization$87.89 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive PRPH News and Ratings via Email

Sign-up to receive the latest news and ratings for ProPhase Labs and its competitors with MarketBeat's FREE daily newsletter.

ProPhase Labs logo

About ProPhase Labs

ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter (OTC) consumer healthcare products and dietary supplements in the United States. It offers a range of OTC dietary supplements, including Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support product; and Super ProstaFlow+ a supplement to support prostate and urinary health under the TK Supplements brand. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; and offers SARS-CoV-2 (COVID-19) and COVID-19 viral mutation PCR tests through saliva and nasal swab methods, as well as other respiratory pathogen panel testing services, including Influenza A and B, and others. It serves consumer products companies, as well as large national chain, regional, specialty, and local retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was incorporated in 1989 and is headquartered in Garden City, New York.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.52 out of 5 stars

Medical Sector

557th out of 2,102 stocks

Pharmaceutical Preparations Industry

269th out of 832 stocks

Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

ProPhase Labs (NASDAQ:PRPH) Frequently Asked Questions

Is ProPhase Labs a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProPhase Labs in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ProPhase Labs stock.
View analyst ratings for ProPhase Labs
or view top-rated stocks.

What stocks does MarketBeat like better than ProPhase Labs?

Wall Street analysts have given ProPhase Labs a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ProPhase Labs wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is ProPhase Labs' next earnings date?

ProPhase Labs is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for ProPhase Labs

How were ProPhase Labs' earnings last quarter?

ProPhase Labs, Inc. (NASDAQ:PRPH) issued its earnings results on Thursday, May, 13th. The company reported $0.23 EPS for the quarter, missing the consensus estimate of $0.35 by $0.12. The business earned $15.27 million during the quarter, compared to analysts' expectations of $11.23 million. ProPhase Labs had a negative net margin of 0.93% and a positive trailing twelve-month return on equity of 12.01%.
View ProPhase Labs' earnings history

How has ProPhase Labs' stock price been impacted by COVID-19?

ProPhase Labs' stock was trading at $2.0301 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PRPH shares have increased by 185.7% and is now trading at $5.80.
View which stocks have been most impacted by COVID-19

How often does ProPhase Labs pay dividends? What is the dividend yield for ProPhase Labs?

ProPhase Labs announced a dividend on Thursday, May 13th. Investors of record on Tuesday, May 25th will be paid a dividend of $0.30 per share on Thursday, June 3rd. The ex-dividend date is Monday, May 24th. This is a boost from ProPhase Labs's previous dividend of $0.25.
View ProPhase Labs' dividend history

What price target have analysts set for PRPH?

1 Wall Street analysts have issued 1-year price objectives for ProPhase Labs' stock. Their forecasts range from $25.00 to $25.00. On average, they expect ProPhase Labs' stock price to reach $25.00 in the next twelve months. This suggests a possible upside of 331.0% from the stock's current price.
View analysts' price targets for ProPhase Labs
or view top-rated stocks among Wall Street analysts.

Who are ProPhase Labs' key executives?

ProPhase Labs' management team includes the following people:
  • Mr. Ted William Karkus, Chairman & CEO (Age 62, Pay $445k)
  • Ms. Monica Brady, Chief Financial Officer (Age 44, Pay $213.08k)

What is Ted Karkus' approval rating as ProPhase Labs' CEO?

2 employees have rated ProPhase Labs CEO Ted Karkus on Ted Karkus has an approval rating of 100% among ProPhase Labs' employees. This puts Ted Karkus in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of ProPhase Labs' key competitors?

What other stocks do shareholders of ProPhase Labs own?

What is ProPhase Labs' stock symbol?

ProPhase Labs trades on the NASDAQ under the ticker symbol "PRPH."

Who are ProPhase Labs' major shareholders?

ProPhase Labs' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (1.92%), Wedge Capital Management L L P NC (0.79%), Kamunting Street Capital Management L.P. (0.65%), Bank of New York Mellon Corp (0.60%), Geode Capital Management LLC (0.54%) and Acadian Asset Management LLC (0.40%). Company insiders that own ProPhase Labs stock include Jason Michael Barr, Louis Md Gleckel and Ted William Karkus.
View institutional ownership trends for ProPhase Labs

Which major investors are selling ProPhase Labs stock?

PRPH stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp.
View insider buying and selling activity for ProPhase Labs
or view top insider-selling stocks.

Which major investors are buying ProPhase Labs stock?

PRPH stock was acquired by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC, Kamunting Street Capital Management L.P., Bank of New York Mellon Corp, Acadian Asset Management LLC, FNY Investment Advisers LLC, Geode Capital Management LLC, Dimensional Fund Advisors LP, and Perritt Capital Management Inc.. Company insiders that have bought ProPhase Labs stock in the last two years include Jason Michael Barr, and Louis Md Gleckel.
View insider buying and selling activity for ProPhase Labs
or or view top insider-buying stocks.

How do I buy shares of ProPhase Labs?

Shares of PRPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ProPhase Labs' stock price today?

One share of PRPH stock can currently be purchased for approximately $5.80.

How much money does ProPhase Labs make?

ProPhase Labs has a market capitalization of $87.89 million and generates $14.51 million in revenue each year. The company earns $-2,130,000.00 in net income (profit) each year or ($0.20) on an earnings per share basis.

How many employees does ProPhase Labs have?

ProPhase Labs employs 95 workers across the globe.

What is ProPhase Labs' official website?

The official website for ProPhase Labs is

Where are ProPhase Labs' headquarters?

ProPhase Labs is headquartered at 621 NORTH SHADY RETREAT ROAD, DOYLESTOWN PA, 18901.

How can I contact ProPhase Labs?

ProPhase Labs' mailing address is 621 NORTH SHADY RETREAT ROAD, DOYLESTOWN PA, 18901. The company can be reached via phone at 215-345-0919 or via email at [email protected]

This page was last updated on 6/17/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.